Why the study?
Subcutaneous fat beneath the lead and generator can challenge defibrillation threshold testing, raising concerns about extravascular ICD performance in patients with obesity.
Is extravascular implantable cardioverter-defibrillator (EV-ICD) implantation feasible and effective in achieving successful defibrillation threshold testing in patients with class III obesity (BMI > 45 kg/m²)?
Is extravascular implantable cardioverter-defibrillator (EV-ICD) implantation feasible and effective in achieving successful defibrillation threshold testing in patients with class III obesity (BMI > 45 kg/m²)?
Extravascular ICD implantation demonstrated favorable defibrillation threshold testing (30 J) and low high-voltage impedance in two patients with class III obesity (BMI > 45 kg/m²), suggesting it is a promising alternative to subcutaneous ICDs in this population.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for EV-ICD in class III obesity; larger prospective studies needed before practice change.
One of the challenges with the subcutaneous implantable cardioverter-defibrillator (S-ICD) is the amount of subcutaneous fat beneath the lead and generator during implantation, which can affect defibrillation threshold (DFT) testing. The extravascular ICD (EV-ICD), created to address many of the limitations of the S-ICD, carried a similar concern given its external placement. Importantly, in the EV-ICD Pivotal trial there was no statistical difference in implant DFT success by body mass index (BMI), height, or weight.
No takes yet. Share an insight, caveat, or question.
Gutiérrez et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: